http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#Head http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion http://purl.obolibrary.org/obo/DOID_2957 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2957 http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00330 http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association http://www.w3.org/2000/01/rdf-schema#label ethambutol hci is indicated for the treatment of pulmonary tuberculosis it should not be used as the sole antituberculous drug but should be used in conjunction with at least one other antituberculous drug selection of the companion drug should be based on clinical experience considerations of comparative safety and appropriate in vitro susceptibility studies in patients who have not received previous antituberculous therapy ie initial treatment the most frequently used regimens have been the following ethambutol hci plus isoniazid ethambutol hci plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy mycobacterial resistance to other drugs used in initial therapy is frequent consequently in such retreatment patients ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies antituberculous drugs used with ethambutol hci have included cycloserine ethionamide pyrazinamide viomycin and other drugs isoniazid aminosalicylic acid and streptomycin have also been used in multiple drug regimens alternating drug regimens have also been utilized http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00330 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig http://purl.org/nanopub/x/hasSignature ddIQY5D+AJSnoBJcYAqS7n1k2HYcvc1Ma5OStx4ElLzNJysqwWoGnuZIFUvxN0M+LeeL5E1AGNaRoSNymWNkeG1mrSmRFPeIy/kJ34qc78L3bk+DO0vtYxsFrVi2MnsJ5NIjjrfJRpQi1eAf/7Pw3DDWDhLWAf7cFsijMWbKWas= http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://purl.org/dc/terms/created 2021-06-29T08:05:23.509+02:00 http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs